Bibliographic citations
Gamero, M., (2019). Eficacia y seguridad de los nuevos anticoagulantes orales comparado con heparina de bajo peso molecular en enfermedad tromboembólica en pacientes con cáncer activo. Revisión sistemática y metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/5334
Gamero, M., Eficacia y seguridad de los nuevos anticoagulantes orales comparado con heparina de bajo peso molecular en enfermedad tromboembólica en pacientes con cáncer activo. Revisión sistemática y metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2019. https://hdl.handle.net/20.500.12759/5334
@misc{renati/1353584,
title = "Eficacia y seguridad de los nuevos anticoagulantes orales comparado con heparina de bajo peso molecular en enfermedad tromboembólica en pacientes con cáncer activo. Revisión sistemática y metaanálisis",
author = "Gamero Arana, María José",
publisher = "Universidad Privada Antenor Orrego",
year = "2019"
}
Objective: to compare the efficacy and safety of new oral anticoagulants versus low molecular weight heparin in the treatment of thromboembolic disease in patients with active cancer. Materials and methods: A Systematic Review of Clinical Trials was performed using Pubmed, Cochrane CENTRAL, MEDLINE and EBSCO. Two independent authors performed article selection, risk assessment of bias and data extraction. The efficacy outcome was recurrent VTE, and the safety outcome was major bleeding, no major clinically relevant bleeding and total bleeding. The incidence and risk ratios (RR) were calculated for patients treated with NOAC and with LMWH separately for meta-analysis. Results: 495 studies were reviewed in title and summary, 13 in full text and 2 were selected for qualitative and quantitative analysis. The meta-analysis showed that NOACs have lower recurrence of VTE compared to LMWH (RR = 0.64; 95% CI 0.46-0.91), however, they have a higher risk of major bleeding (RR = 1.75; 95% CI 1.10-2.77). Regarding clinically relevant no major bleeding (RR = 2.01; 95% CI 0.76-5.30) and total bleeding (RR = 1.83; 95% CI 0.90-3.71) no significant difference was found between both treatments. Conclusions: NOACs (rivaroxaban and edoxaban) are more effective in preventing the recurrence of thromboembolic events compared to LMWH, as well as a safety comparable to LMWH, associated with an increased risk of major bleeding, as well as a tendency to greater clinically relevant no major bleeding and total bleeding.
This item is licensed under a Creative Commons License